natgillin/translations-raw huggingface dataset:
In one embodiment of the methods provided above, the one or more cells is cultured in at least 100 L of the supplemented basal cell culture media. In one embodiment of the methods provided above, the cell density is maintained at less than 2.5×106 cells per mL during the step of culturing the one or more cells. In one embodiment of the methods provided above, the cell density is maintained at less than 2.0×106 cells per mL during the step of culturing the one or more cells. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što se jednu ili više stanica uzgaja u najmanje 100 1 kompletiranog osnovnog medija za uzgoj stanica. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što se gustoću stanica održava kod manje od 2,5 x 10" stanica na ml u koraku uzgoja jedne ili više stanica, manje od 2,0 x 10" stanica na ml u koraku uzgoja jedne ili više stanica, ili manje od 1,5 x 10" stanica na ml u koraku uzgoja jedne ili više stanica.
In one aspect, the invention features a method of identifying a subject at risk of developing PML, such as by obtaining a biological sample from the subject; contacting the biological sample with HPVLPs under conditions suitable for binding of a JC Virus (JCV) antibody in the sample to an HPVLP; detecting the level of JCV antibody binding in the sample to HPVLPs; and correlating the detected level with a reference set, wherein the subject is at increased risk of PML if JCV antibody binding is detected. 
(c) detektiranju razine protutijela protiv JCV u predinkubiranom uzorku koja se vežu na imobilizirane HPVLP-e; 1 (d) uspoređivanju detektirane razine protutijela protiv JCV u predinkubiranom biološkom uzorku s razinom protutijela protiv JCV detektiranom u biološkom uzorku dobivenom iz subjekta predinkubiranom u otopini bez HPVLP-a, te stavljenom u kontakt s HPVLP imobiliziranim na čvrsti supstrat u uvjetima pogodnim za vezanje protutijela protiv JCV u uzorku na HPVLP, gdje se HPVLP-i sastoje od više od 5, najmanje 50, 150 ili 360 polipeptida VP1.
Inecalcitol for the use according to claim 6 wherein said further administration(s) is (are) simultaneous, separate or sequential with that of inecalcitol. 
Inekalcitol, namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što jedna ili više navedenih dodatnih primjena su istodobne, odvojene ili uzastopne onoj inekalcitola.
contacting a GPR119 agonist in vitro with a mammalian enteroendocrine cell; and 
(a) stavljanje u kontakt GPRI 19 agonista in vitro s enteroendokrinom stanicom sisavca; te
Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. 
Iako je u praksi ili za ispitivanje ovog izuma moguće koristiti bilo koje postupke i materijale koji su slični ili ekvivalentni ovdje opisanima, ovdje su opisani poželjni postupci, sredstva i materijali.
The solution was stirred to dissolve the solids then CH2(OCH3)2 (0.515mmol, 5eq.) 
Otopina je bila miješana da bi se otopile krutine i tada je bio dodan CHX(OCH:) (0.515 mmol, 5 ekv.)
An anti-Factor XI (FXI) monoclonal antibody, or a fragment of such an antibody wherein said fragment is biologically active, which antibody: specifically binds to an epitope on the heavy chain of human FXI described in SEQ ID NO:1, wherein said antibody is biologically active; or 
Izolirano monoklonsko protutijelo ili njegov fragment koji veže antigen, naznačeno time, da se specifično veže na ljudski faktor koagulacije XI (FXI) opisan u SEQ ID NO: 1, pri čemu protutijelo ili fragment inhibira trombozu bez nanošenja štete sustavu hemostaze, te time da navedeno protutijelo:
conveying said thermally insulating stretchable down feather sheet (10) outof said thermal chamber (39) as a continuoussheet. 
transporta navedenog toplinski izolirajućeg rastezljivog sloja paperja (10) iz navedene toplinske komore (39) kao kontinuiranog sloja.
The process defined in claim 1 wherein according to step (iii) the acidic treatment is carried out with 2 equivalents of oxalic acid dihydrate. 
Postupak u skladu sa gornjim zahtjevima, naznačen time, da se provodi tretiranje kiselinom u stupnju iii) s 2 ekvivalenta dihidrata oksalne kiseline.
The container according to claim 1 wherein said tab portion extends radially downward away from the protuberance and along the shoulder. 
Kontejner prema zahtjevu 1, pri čemu se spomenuti dio u obliku jezičca pruža radijalno naniže suprotno od ispupčenja i duž oboda.
The method according to claim 16, wherein the pharmaceutical composition is for the treatment of progressive tumors, late stage tumors, tumor patients with high tumor load/burden, metastatic tumors, or tumor patients with a CEA serum concentration higher than 100 ng/ml. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 24 do 26, naznačena time što je farmaceutski pripravak namijenjen liječenju uznapredovalih tumora, kasnog stadija tumora, tumorskih pacijenata visoko opterećenih tumorom, metastazirajućih tumora ili tumorskih pacijenata s koncentracijom CEA u serumu višom od 100 ng/ml.
The controller (10) of claim 1, wherein rotation of said second flange (16) with respect to said first flange (14) is configured to cause said vehicle to accelerate or decelerate. 
Upravljač (10) sukladno zahtjevu 1, pri čemu okretanje drugog elementa (16) u odnosu na prvi element (14) dovodi do ubrzavanja ili usporavanja vozila.
An immunogenic composition according to claim 16 or claim 17 further comprising an adjuvant, optionally wherein the adjuvant is AS01 for instance, AS01B or AS01E. 
Imunogeni pripravak u skladu s patentnim zahtjevom 16 ili patentnim zahtjevom 17, naznačen time što dodatno sadrži adjuvans, gdje adjuvans može biti AS01, primjerice AS01B ili AS01E.
a second domain of said at least two domains comprises an amino acid sequence consisting of at least 350 amino acid residues forming random coil conformation as determined by circular dichroism spectroscopy measurement, whereby said random coil conformation mediates an increased in vivo and/or in vitro stability of said biologically active protein. The biologically active protein according to claim 1, wherein said second domain forming random coil conformation consists of alanine, serine and proline residues. 
druga domena od navedene najmanje dvije domene sadrži aminokiselinski slijed, kojeg čine najmanje otprilike 100 aminokiselinskih ostataka, koji čine konformaciju nasumične zavojnice, te gdje navedenu drugu domenu čine alaninski, serinski i prolinski ostaci gdje navedena konformacija nasumične zavojnice uzrokuje povećanu stabilnost navedenog biološki aktivnog proteina in vivo i/ili in vitro.
Typical aryl groups contain from 1 to 3 separated or fused rings and from 6 to about 18 carbon ring atoms. 
Tipične aril grupe sadrže od 1 do 3 odvojena ili fuzionirana prstena i od 6 do oko 18 ugljikovih atoma u prstenu.
Process according to claim 1, wherein the pretreated palm fruit oil product is simultaneously contacted with the bleaching earth and the porous silica material. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se predobrađeno ulje kao proizvod palminog ploda istodobno stavlja u kontakt s izbjeljujućom zemljom 1 s poroznim silikatnim materijalom.
Antibody or antibody molecule composition according to claim 30, wherein said antibody binds the glycosylated epitope with a higher affinity than the non-glycosylated epitope. 
protutijelo u skladu s (b) koje se veže na glikozilirani epitop s većim afinitetom nego na neglikozilirani epitop; i/ili
It should be noted that the described recycling device can also comprise other mixture treatment stages upstream of the extrusion stage, such as depolythenization treatment; depulverization treatment; 
Trebalo bi napomenuti da opisani uređaj za recikliranje može također imati druge stupnjeve za obradu navedene mješavine, koji se nalaze u smjeru suprotno od smjera odvijanja postupka od stupnja za ekstruziju, takve stupnjeve postupaka kao što su
The device of claim 1, wherein cooled rollers arranged in a region of the flame drying station below the film web are provided, which rollers serve as support rollers for the film web. 
Naprava u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se u području stanice za sušenje plamenom ispod folije (2) nalaze hlađeni valjci, koji služe kao valjci za prijenos folije.
The method of claim 4, wherein the step of storing comprises storing the polypropiolactone for at least 1 week. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se korak skladištenja sastoji u skladištenju polipropiolaktona u trajanju od najmanje tjedan dana.
In a further embodiment the present invention relates to the use of a compound of formula I, IA, IB, IC, ID or IE as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of attention deficit hyperactivity disorder. 
U jednom daljnjem obliku ovaj se izum odnosi na korištenje spoja formule I, IA, IB, ili IC kao slobodne baze ili njezine soli za pripravak farmaceutskog sastava kod liječenja smetnji hiperaktivnosti s deficitom pažnje.
Furthermore, as can be appreciated, a friction fit, sealable cap 25 would allow mixture in bottle 20 to be stored for some reasonable time, as opposed to having to throw it away if not used up in a given application session. 
Uz to, podrazumijeva se da će frikcijski brtveni poklopac 25 omogućiti da se mješavina u boci 20 može uskladištiti na neko prihvatljivo vrijeme, a ne baciti ako nije utrošena u tijeku jednog postupka nanošenja. 3. Nosač 30 boce
wherein the ciclesonide or the pharmaceutically acceptable salt thereof or the composition comprising ciclesonide or the pharmaceutically acceptable salt thereof is administered at a dose of 100 ug to 5000 ug ex inhaler. The method of claim 1, wherein the airway disease is a pulmonary disease. The method of claim 1, wherein the airway disease is selected from the group consisting of recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD). 
Ciklezonid ili njegova farmaceutski prihvatljiva sol ili pripravak koji sadrži ciklezonid ili njegovu farmaceutski prihvatljivu sol prema zahtjevu 1 ili 2, naznačen time, da je za uporabu u postupku kod liječenja bolesti dišnih puteva kod Equinae, poželjno konja, gdje se bolest dišnih puteva bira iz skupine koja se sastoji od: rekurentne opstrukcije dišnih puteva (RAO, prema engl. «recurrent airway obstruction»), opstruktivne plućne bolesti povezane s ljetnom ispašom (SPAOPD, prema engl. «summer pasture associated obstructive pulmonary disease»), te inflamatorne bolesti dišnih puteva (IAD, prema engl. «inflammatory airway disease»).
In humans we obtained encouraging results with a ratio of 5:1 in the tolperisone-dextromethorphan combination. 
Za ljude smo dobili ohrabrujuće rezultate s omjerom od 5:1 u kombinaciji tolperisona i dekstrometorfana.
Use of a powder as a setting accelerator for a dry mortar blend, the powder comprising calcium nitrate, wherein the powder has a water content between 0,1% and 20% and a particle size of 0.1 mm to 1 mm. 
Uporaba praha kao akceleratora vezivanja za smjesu suhog morta, prašak sadržava kalcij nitrat, naznačena time, da je udjel vode u prašku između 0,1 % 120 %, a veličina čestica praška od 0,1 mm do 1 mm.
The statistical examination (Student t) has revealed no significant difference between the medicated group and the control group (the group not medicated but with high cholesterol diet) in regard to plasma lipid. 
Statističko ispitivanje (Student t) nije pokazalo nikakvu značajnu razliku između liječene skupine i kontrolne skupine (skupine koja nije primala lijek već samo hranu s visokim sadržajem kolesterola) u pogledu lipida u plazmi.
a higher amount of non-fucosylated structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of said antibody molecules in said antibody molecule composition which is at least 50% higher compared to the same amount of antibody molecules in at least one antibody molecule composition of the same antibody molecule isolated from CHOdhfr- [ATCC No. 
(ili) veću količinu nefukoziliranih struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 50% veća u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
Compositions for use in treatment and prevention of diseases caused by DNA enveloped, DNA non-enveloped, RNA enveloped, RNA non-enveloped viruses are presented. 
Lavendulola u farmaceutski učinkovitoj koncentraciji za upotrebu u liječenju i prevenciji bolesti uzrokovanih virusima obavijenim sa DNK, virusima neobavijenim sa
and R5 for each occurrence is, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; 
i R5 za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil;
Also in still another embodiment of aspect 3 to be in particular emphasized, the present invention refers to an acid addition salt of (E)-N-hydroxy-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide with any acid selected from the group consisting of toluenesulphonic acid, benzenesulfonic acid and naphthalene-2-sulfonic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (E)-N-hidroksi-3-[1-(5-piridin-2-iltiofen-2-sulfonil)-1Z7-pirol-3-iljakrilamida s bilo kojom od kiselina koje se bira iz skupine koju čine metansulfonska kiselina, etansulfonska kiselina, toluensulfonska kiselina, benzensulfonska kiselina i naftalen-2-sulfonska kiselina, ili njegov hidrat.
A process for obtaining a pharmaceutical composition containing a mixture of glatiramer acetate, and wherein the mixture has a desired average molecular weight, which comprises 
Postupak za dobivanje farmaceutskog sastava koji sadrži glatiramer acetat, naznačen time, da sadrži
The isolated cell of claim 9, wherein said cell is additionally negative for expression of a-smooth muscle actin, negative for expression of RANKL, positive for expression of NG2, positive for expression of osteoprotegerin, and exhibits inducible alkaline phosphatase activity. 
Izolirana stanica u skladu s patentnim zahtjevom 9, naznačena time što je navedena stanica uz to negativna na ekspresiju a-aktina iz glatkih mišića, negativna na ekspresiju RANKL, pozitivna na ekspresiju NG2, pozitivna na ekspresiju osteoprotegerina, te pokazuje imducibilnu aktivnost alkalne fosfataze.
In the case of temperature fluctuations, the tube 13 and the rod 14 undergo different linear expansions in their longitudinal direction, thus resulting in a relative movement in the direction of movement B. Since the lower end of the rod 14 is either pressed into the tube 13 with a spring force acting from above or is even fixed, for example clamped, in said tube, a longitudinal movement results at the upper end of the two parts. 
Temperaturni senzor prema zahtjevu 1, naznačen time, da se štap (14) oslanja na prvu presklopnu oprugu (20) pomoću međuelementa (18, 19) kako bi bio otponac za spomenutu oprugu, pri čemu je poželjno pripremljena metalna igla na kraju cijevi koja podešava otponski položaj uključenja prve presklopne opruge (20), dok se ta metalna igla se može pokretati u uzdužnom smjeru cijevi, kada još nije pričvršćena 1 na tu iglu se oslanja štap.
It is further provided a controlled cooling system for cooling the sheets before the withdrawal device 14 ′. 
Nadalje, omogućen je kontrolirani sustav hlađenja limova prije uređaja 14". HR P20080586 T3
A process according to claim 2 wherein the amination of 1,1-cyclohexanediacetic acid anhydride takes place by reaction with ammonia in aqueous solution with a concentration 28%. 
Postupak prema zahtjevu 2 gdje se aminacija anhidrida 1,1-cikloheksandioctene kiseline odvija reakcijom s amonijakom u vodenoj otopini u koncentraciji od 28%.
Unilateral injection of kainic acid (1 nmol in 50 mL) into the dorsal hippocampus in mice induces a non-convulsive status that results in spontaneous recurrent focal seizures after 2-3 weeks. 
Unilateralna injekcija kainske kiselina (1 nmol in 50 mL) u dorzalni hipokampus kod miševa inducira nekonvulzivni status koji dovodi do spontanih periodičnih fokalnih napada tijekom 2-3 tjedna.
The compound for use according to claim 10, wherein the neurodegenerative disease is Alzheimer's disease or multiple sclerosis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je neurodegenerativna bolest Alzheimerova bolest ili multipla skleroza.
The process of any one of claims 1-4 wherein the carrier protein is selected from the group consisting of tetanus toxoid, fragment C of tetanus toxoid, diphtheria toxoid, CRM197, Pneumolysin, protein D, PhtD, PhtDE and N19. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što se protemski nosač bira iz skupine koju čine tetanusni toksoid, fragment C tetanusnog toksoida, difterijski toksoid, CRM197, pneumolizin, protein D, PhtD, PhtDE i N19.
Vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein a first fragment of said at least two fragments comprises at least 9 consecutive amino acid residues of amino acid residues 153 to 165 of PCSK9 according to SEQ ID No. 9 and a second fragment of said at least two fragments comprises at least 9 consecutive amino acid residues of amino acid residues 209 to 222 of PCSK9 according to SEQ ID No. 9. 
Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje osam uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 150 do 170 od PCSK9 u skladu sa SEQ ID NO:9, i gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje osam uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 205 do 225 od PCSK9 u skladu sa SEQ ID NO:9.
An isolated nucleic acid molecule encoding a bispecific binding molecule comprising the amino acid sequence shown in SEQ ID NO: 207. 
Bispecifična vezna molekula, naznačena time, da ima aminokiselinsku sekvencu prema SEQ ID NO: 207 (VEGFANGBII00022).
Furthermore, the present invention refers to the use of a composition comprising one or more aldehyde-releasing and/or aldehyde-based biocides in an amount such that the total amount of aldehyde-releasing and/or aldehyde-based biocides in the aqueous preparation is from 250 ppm to 5000 ppm, calculated relative to the water in the preparation, and 
(a) jedan ili više biocida koji oslobađaju aldehid i/ili biocidi s jednom ili više aldehidnih skupina u količini tako da je ukupna količina biocida koji oslobađaju aldehid i/ili biocida s jednom ili više aldehidnih skupina u vodenom pripravku od 250 ppm do 5000 ppm, izračunato u odnosu na težinu vode u pripravku, te
isolating from the mouse of (ii) an antibody that specifically recognizes the antigen, or isolating from the mouse of (ii) a cell comprising an immunoglobulin domain that specifically recognizes the antigen, or identifying in the mouse of (ii) a nucleic acid sequence encoding a heavy and/or light chain variable domain that binds to the antigen. 
izoliranja iz miša prema (b) antitijela koje specifično prepoznaje antigen, ili izoliranja iz miša prema (b) stanice koja sadrži imunoglobulinsku domenu koja specifično prepoznaje antigen, naznačeno time, što antitijelo sadrži teški lanac dobiven iz humanog segmenta gena Vh, humanog segmenta gena Dh, humanog segmenta gena JH i mišjeg gena CH te laki lanac dobiven iz humanog segmenta gena Vλ, humanog segmenta gena Jλ i mišjeg gena Ck.
a conduit allowing gravitational flow of water from a source basin to a recipient basin when the pumping system is inactive; and 
(Cc) cijev koja omogućuje gravitacijski protok vode od izvornog bazena do prijemnog bazena kada je sustav za pumpanje neaktivan; i
Compounds that form a lactone, like the statins, may exist either in the free acid form or the lactone form or in an equilibrium mixture of both forms. 
Spojevi koji oblikuju lakton, kao statini, mogu postojati u obliku slobodne kiseline ili u obliku laktona, ili u ravnotežnoj smjesi oba oblika.
The method according to claim 1, characterized in that said step for constructing an upper shoe assembly comprises the association of said upper membrane (14) with said upper (13) so as to not compromise their vapor permeability, such as by spot gluing or the like. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se navedena faza izrade gornjišta cipele sastoji od spajanja navedene membrane gornjišta (14) s navedenim gornjištem (13) na način da se ne ugrožava njihovo svojstvo paropropusnosti, primjerice točkastim lijepljenjem ili sličnim postupkom.
As stated in paragraph [0127] herein, antibodies and fragments thereof may be modified post-translationally to add effector moieties such as chemical linkers, detectable moieties such as for example fluorescent dyes, enzymes, substrates, bioluminescent materials, radioactive materials, and chemiluminescent moieties, or functional moieties such as for example streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, and radioactive materials. 
(ii) dodatno sadrži efektorski ostatak koji je detektibilni ostatak ili funkcionalni ostatak, gdje navedeni detektibilni ostatak može biti fluorescentno bojilo, enzim, supstrat, bioluminescentni materijal, radioaktivni materijal, ili kemiluminescentni materijal, navedeni funkcionalni ostatak može biti streptavidin, avidin, biotin, citotoksin, citotoksično sredstvo, ili radioaktivni materijal.
The sole for shoes according to claim 2, wherein said net elements are rigidly coupled to said lower element by overmolding of said lower element on edges of said net elements, which are arranged in the mold as inserts, parts of said lower element which are superimposed on the perimetric edges of said net elements, constituting said undercut regions for preventing downward extraction for said net elements. 
Potplat za cipele u skladu s patentnim zahtjevom 2, naznačen time, da su navedeni mrežasti elementi (20) kruto spojeni na navedeni donji element (11) tako što se navedeni donji element (11) preša i oblikuje preko rubova navedenih mrežastih elemenata (20) koji su postavljeni u kalup kao umeci, a dijelovi navedenog donjeg elementa